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physician. A recommended approach5 is to educate
patients about the disorder and effective psychiatric
treatment. It is probably best to avoid cosmetic
procedures. Simply trying to talk patients out of their
concern is usually futile.
Although body dysmorphic disorder has been
described for over a century and reported around the
world, it remains underrecognised and underdiag›
nosed.2 Men and boys are often reluctant to reveal their
symptoms because of embarrassment and shame, and
they typically do not recognise that their beliefs about
their appearance are inaccurate and due to a psychiat›
ric disorder. Physicians can diagnose body dysmorphic
disorder in men with a few straightforward ques›
tions.5 12 These determine whether the man is
concerned about and preoccupied with minimal or
non›existent flaws in his appearance and whether this
concern causes significant distress (depression, anxiety)
or interferes with social, occupational, or other aspects
of functioning. The challenge is to enhance both phy›
sicians’ and the public’s awareness of body dysmorphic
disorder so that effective treatments can be offered and
unnecessary suffering and morbidity avoided.
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Tackling coronary heart disease
A gender sensitive approach is needed
Coronary heart disease is the commonest causeof death in the United Kingdom, with markedgender differences in incidence, presentation,
referral, recovery, and rehabilitation.1–6 Current policy
on coronary heart disease is written in gender neutral
language at a time when treatment has been moving
towards a more behavioural model, where cardiac
rehabilitation is a therapeutic option and changing
cardiac health behaviour a major objective. Given the
importance of this there is a need for health strategy
that is gender sensitive.
The government views the national service
framework for coronary heart disease as its “blueprint”
for tackling heart disease.7 It lays out 12 standards and
sets out services that should be available throughout
England. Although the framework acknowledges
gender differences, there is no clear recognition in the
guidelines of how these are to be addressed.
In part this is due to the evidence on which the
guidelines have been based. Relatively small numbers
of women, older people (both men and women), and
ethnic minorities have been included in biomedical
research into coronary heart disease, which has largely
ignored women and treated white low risk men
presenting with their first acute episode as a
convenient sample. This is possibly due to the difficul›
ties associated with controlling for comorbidity in
older men and women, and the ethical and legal prob›
lems associated with fertile women who may be
pregnant.8 Therefore it has been customary to apply
the conclusions of research to populations not studied,
since it has been thought reasonable to assume there is
no biologically plausible reason to expect findings to
vary between the sexes. There is evidence, however, that
women have not been well catered for by services
underpinned by existing research. Studies that have
included women appear to have had deficiencies in
recognising and treating coronary heart disease.5
These difficulties for women are compounded by
the existing consensus among both the public and
health professionals that coronary heart disease is a
disease of men.9 10 In a recent study in which women
with coronary heart disease were interviewed, one
participant talked of men she knew being potential
coronary candidates but she did not view herself as at
risk as she was a woman and could not think of any
famous women who had had a heart attack.11
The current research focus therefore has meant
that women’s experience has not been captured and
used in service delivery—but neither, it may be argued,
has men’s. Despite most research being undertaken on
men we are not much closer to an understanding of
how men experience coronary heart disease. This is
due to the failure of much research to acknowledge the
gender sensitive nature of coronary heart disease and
thus to treat gender as a variable to be controlled. Gen›
der effectively becomes invisible, resulting in research
that does not consider the issue of masculinity and
men’s acknowledged difficulty in managing their
health.12 13 Despite coronary heart disease being
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stereotyped as a male disease, men display a high
degree of ignorance and avoidance of both coronary
heart disease and the risk factors associated with it. For
instance, though women may avoid considering their
risk of developing coronary heart disease by assuming
it is a male disease, men too delay in seeking medical
help when experiencing chest pain.5 14 Thus coronary
heart disease is the greatest cause of premature death
in men, yet it is relatively unresearched from the
perspective of men’s health behaviour.
Though the aims as set out in the national service
framework are laudable, the fact that the framework
does not include male and female specific standards
makes it harder to create the environment for research
and health strategy development that addresses men
and women’s separate needs. This is already evident by
the relative dearth of social research into gender and
coronary heart disease. Both women’s health
groups and the Men’s Health Forum (www.
men’shealthforum.org.uk) have noted that only a few
practitioners have set up gender sensitive initiatives.
Gender must be seen as an important factor in
health care planning and delivery. Coronary heart dis›
ease is a prime example of where there are known
gender differences. We need investment in research
and inclusion of gender within educational pro›
grammes, without which health professionals will
remain ignorant of the problems created by gender
neutral health care.
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Prophylactic treatment of anthrax with antibiotics
Indiscriminate use of antibiotics will lead to resistance in organisms
Bacillus anthracis has long been considered apotential biological weapon. The Scottish islandof Gruinard was contaminated with spores for 45
years and the Aum Shinrikyo terrorists made unsuccess›
ful attempts to release aerosols of anthrax and
Clostridium botulinum spores in Tokyo.1 In addition,
anthrax spores were inadvertently released from a
microbiological facility in Sverdlovsk in the former
Soviet Union, resulting in at least 79 people getting
anthrax and 68 deaths.1 In response to the recent
anthrax attacks in the United States, the US and other
governments have bought large amounts of cipro›
floxacin, and in the US many potentially exposed
individuals have started prophylactic treatment. Unoffi›
cial use of ciprofloxacin will be common in the light of
the worldwide panic. Ciprofloxacin has been chosen to
treat anthrax for its ease of administration, good safety
profile, and predictable activity. The alternatives are
amoxicillin or doxycycline, but these too have side effects
and can induce resistance. The important thing is to
ensure that prophylactic treatment is given only to those
who really need it, and to discourage its mass use by an
understandably alarmed public. Indiscriminate use of
antibiotics can induce resistance in B anthracis and other
organisms. To induce antimicrobial resistance on a mass
scale would be an even greater triumph for the terrorists.
Anthrax is a zoonosis, accidentally transmitted
from herbivores to humans with no onward person to
person transmission. The clinical presentation and
outcome depend on the route by which anthrax is
acquired.1 Cutaneous anthrax, which is the commonest
form (95% of patients), follows inoculation of spores
into damaged skin and has the best outcome, with less
than 1% mortality. Eating badly cooked meat contami›
nated with anthrax spores leads to oropharyngeal or
gastrointestinal anthrax. This is the least common form
but has a high mortality. Inhalation of spores leads to
pulmonary anthrax, which is usually fatal.
B anthracis, including the strains isolated from the
recent cases in the US, is sensitive in vitro to a range of
antimicrobials, including penicillin, amoxicillin, doxy›
cycline, tetracycline, clarithromycin, clindamycin, and
ciprofloxacin. Benzylpenicillin is the treatment of
choice, but treating anthrax after inhalation of spores is
particularly difficult since the disease progresses
rapidly to death. This has led to the introduction of
chemoprophylaxis for individuals at risk.1 2
In animal models, penicillin, ciprofloxacin, or doxy›
cycline given 24 hours after exposure to a lethal aero›
sol provided significant protection against death, but
combining antimicrobials with vaccination provided
optimal protection.3 Currently oral ciprofloxacin is
recommended after known exposure to spores.1 2
Disease can present 50 days or more after exposure,1
so prophylaxis should continue for 60 days unless
exposure has been excluded.
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